Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 7.01, 9.01 · 8-K

Opus Genetics, Inc.

IRDNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 11, 2026, Opus Genetics, Inc. (the “Company”) issued a revised version of the Company’s data presentation, which was initially used in connection with its investor conference on September 9, 2026, announcing clinical data from Cohort 1 of the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases.…

Filed Sep 11, 2026Accepted Sep 11, 2026, 7:48 AM EDTCIK 1228627Accession 0001140361-26-036277
Share

Company context

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with OPGx-RDH12 cleared to enter the clinic, and additional candidates targeting MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Current securities

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Opus Genetics, Inc.Nov 16, 2026
  2. SCHEDULE 13G/A - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Opus Genetics, Inc.Nov 16, 2026
  3. 10-Q filingNov 10, 2026
  4. Results of Operations and Financial ConditionNov 10, 2026
  5. 4 filingOct 27, 2026

Registered securities in this filing

Opus Genetics, Inc. · 8-K · Filed 2026-09-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol
IRD
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c20260911to20260911

Dimensions: Not supplied

Accession 000114036126036277 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 11, 2026, Opus Genetics, Inc. (the “Company”) issued a revised version of the Company’s data presentation, which was initially used in connection with its investor conference on September 9, 2026, announcing clinical data from Cohort 1 of the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases. The original data presentation was furnished by the Company on a Current Report on Form 8-K on September 9, 2026. The revised version of the data presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, corrects an immaterial error in the translation of logMAR visual acuity into ETDRS letters, which impacted the depiction of mean best-corrected visual acuity from baseline through 3 months in Cohort 1 on Slide 15. The correct three month change from baseline for each participant is as follows: 101-101 had a 12 letter improvement in the treated eye and a 4 letter improvement in fellow eye, 101-104 had a 1 letter improvement in the treated eye and a 7 letter loss in the fellow eye, 102-101 had a 10 letter loss in the treated eye and an 8 letter loss in the fellow eye, 102-102 had a 2 letter gain in the treated eye and a 5 letter loss in the fellow eye, and 101-106 had a 6 letter gain in the treated eye and a 2 letter gain in the fellow eye. In addition to the update on Slide 15, high-resolution images of the microperimetry grids for baseline and 3 months were added to the Appendix of the revised presentation for each participant. Individual loci data is available for the three participants in these images.
Filed exhibits (1)
EX-99.1 (by filename) ef20081922_ex99-1.htm

EX-99.1 2 ef20081922_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements related to our continued clinical development, clinical results, preclinical data, and future plans for OPGx-BEST1, including the anticipated timing of dosing completion and topline data from Cohort 2 of the OPGx-BEST1 Phase 1/2 clinical trial; the outcome of our ongoing regulatory interactions with the U.S. Food and Drug Administration (the “FDA”) and our expectations regarding the design of, and potential endpoints for, of any pivotal clinical trial of OPGx-BEST1;…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.